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bjectives The aim of this study was to determine the efﬁcacy and safety of bivalirudin versus low-
ose unfractionated heparin (UFH) in percutaneous peripheral intervention (PPI).
ackground Anticoagulation strategies used in PPI are based primarily on studies of percutaneous
oronary intervention where higher doses of heparin are used usually in combination with a glyco-
rotein IIb/IIIa inhibitor. There are no studies comparing bivalirudin alone versus low-dose heparin
n PPI.
ethods Consecutive patients who underwent PPI at our institution were treated with either biva-
irudin or low-dose UFH. Patients were assessed prospectively during index hospital stay for proce-
ural success and bleeding complications. Of 236 patients, 111 were dosed with UFH at 50 U/kg
goal activated clotting time of 180 to 240 s), and 125 were dosed with bivalirudin at 0.75-mg/kg/h
olus followed by a 1.75-mg/kg infusion. Procedural success was deﬁned as 20% post-procedure
esidual stenosis with no ﬂow-limiting dissections or intravascular thrombus formation and major
leeding as intracranial or retroperitoneal hemorrhage or a fall in hemoglobin 5 g/dl. Anticoagula-
ion cost analysis was conducted.
esults Procedural success and major bleeding rates were similar with bivalirudin versus heparin
98% vs. 99% and 2.4% vs. 0.9%, respectively). There were no differences in minor bleeding, time to
mbulation, and length of hospital stay. The hospital cost for bivalirudin was $547 and $1.22 for
eparin (10,000 U). Two activated clotting time levels cost $4.00.
onclusions Low-dose UFH is as effective and safe as bivalirudin when used as an anticoagulation
trategy in patients undergoing PPI, and low-dose UFH is less costly than bivalirudin. Larger ran-
omized studies are required to further evaluate these ﬁndings. (J Am Coll Cardiol Intv 2009;2:
71–6) © 2009 by the American College of Cardiology Foundation
rom *Aurora Cardiovascular Services, Aurora Sinai/St. Luke’s Medical Centers, University of Wisconsin School of Medicine and
ublic Health-Milwaukee Clinical Campus, Milwaukee, Wisconsin; and the †Center for Urban Population Health, University of
isconsin-Milwaukee, Milwaukee, Wisconsin.anuscript received April 21, 2009; revised manuscript received June 16, 2009, accepted June 25, 2009.
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872pproximately 14 to 16 million Americans suffer from
eripheral arterial disease (1), some of whom will require
ntervention. The goal of any percutaneous peripheral in-
ervention (PPI) is not only to achieve immediate proce-
ural success but also to avoid any post-procedure compli-
ations. Patients with peripheral arterial disease undergoing
PI are at high risk for thrombotic complications. This risk
s reduced with the use of anticoagulation during the
rocedure. However, anticoagulation itself leads to higher
ost-procedure bleeding rates. An ideal anticoagulation
trategy would be one that reduces thrombosis risk with
ittle or no increase in bleeding rates.
Currently, there are no American College of Cardiology/
merican Heart Association guidelines for anticoagulation
n PPI. Anticoagulation strategies used during PPI are
ased primarily on studies conducted for percutaneous
oronary intervention (PCI), in which the safety and efficacy
f unfractionated heparin (UFH) and bivalirudin have been
learly defined (2–6). Some studies have suggested that
ivalirudin offers the same efficacy as UFH but with reduced
ischemic and bleeding complica-
tion rates (5–7). However, in
these studies, relatively higher
doses (up to 70 to 175 U/kg) of
heparin were used, usually in
combination with a glycoprotein
(GP) IIb/IIIa receptor inhibitor.
Large-scale randomized studies
directly comparing in-hospital
efficacy and complication rates
of low-dose heparin versus biva-
lirudin in PPI have not been
conducted. In this prospective
cohort study, we compared the
n-hospital efficacy and safety of low-dose UFH versus
ivalirudin in patients undergoing PPI.
ethods
onsecutive patients undergoing PPI at Aurora Sinai and
urora St. Luke’s Medical Centers in Milwaukee were studied
n a nonblinded, prospective fashion between March and July
008. Patients over the age of 18 requiring noncoronary/
oncarotid PPI met the inclusion criteria. The exclusion
riteria included: 1) acute limb ischemia; 2) use of fibrinolytic
gents or GP IIb/IIIa receptor inhibitors; 3) myocardial in-
arction or stroke in the last 6 months; and 4) contraindication
o use of bivalirudin or heparin. A total of 236 patients were
nrolled. Eight operators alternated the use of bivalirudin and
eparin in consecutive patients; 125 received bivalirudin and
11 received heparin. The institutional review board approved
he protocol.
tudy protocol. Bivalirudin was used at the standard dose of
bbreviations and
cronyms
CT  activated clotting
ime
P  glycoprotein
CI  percutaneous
oronary intervention
PI  percutaneous
eripheral intervention
RBC  packed red blood
ells
FH  unfractionated
eparin.75-mg/kg bolus and 1.75-mg/kg/h infusion. Bivalirudinnfusion was discontinued at the end of the procedure.
eparin was given as a bolus of 50 U/kg with additional
oluses given to maintain an activated clotting time (ACT)
etween 180 and 240 s. The ACT levels were checked at 5
nd 30 min after the bolus. Femoral sheaths were removed
h after bivalirudin infusion was discontinued in patients
ith normal renal function and at ACT 160 s in patients
eceiving heparin. Patients were put on bed rest for 4 to 6 h
fter sheath removal in both groups. Please see Table 1 for
he number of patients receiving pre-procedure acetylsali-
ylic acid (ASA), clopidogrel, and warfarin. Of the patients
aking warfarin in each group, only 1 bivalirudin patient
pre-procedural international normalized ratio 1.6) suffered
minor bleed. Daily dosing of lifelong ASA 325 mg and 1
onth of clopidogrel 75 mg were given to the majority of
atients. Exceptions included superficial femoral artery or
elow-the-knee intervention, in which case clopidogrel
osing was increased to 6 to 12 months, or if the patient was
aking warfarin (for any other medical indication), in which
ase the ASA dose was decreased to 81 mg daily and
uration of clopidogrel dosing was decreased to 2 weeks.
Duration of procedure, largest sheath size used, baseline
enal function, international normalized ratio, and complete
lood count before and after the procedure were all re-
orded. Signs or symptoms of acute thrombosis were mon-
tored, and a duplex ultrasound was performed if clinically
ndicated. Patients were followed while they were in the
ospital to check for any signs or symptoms of bleeding.
ime of sheath removal, time to ambulation, and length of
ospital stay were documented. The overall cost per patient
as calculated for both the heparin and the bivalirudin groups.
tudy end points. Primary study end points included imme-
iate procedural success and in-hospital major bleeding. Pro-
edural success was defined as residual stenosis of20% in the
Table 1. Baseline Demographic Data and Clinical Characteristics
Bivalirudin
(n  125)
UFH
(n  111) p Value
Variable
Age (yrs) 69.9 10.43 71.2 11.88 0.3724
Male 71 (56.8%) 51 (46.0%) 0.1250
CAD 98 (78.4%) 90 (81.1%) 0.7271
Diabetes mellitus 56 (44.8%) 45 (40.5%) 0.5975
Hypertension 96 (76.8%) 82 (73.9%) 0.7114
Dyslipidemia 78 (62.4%) 74 (66.7%) 0.5837
Obesity (BMI 30 kg/m2) 70 (56.0%) 54 (48.7%) 0.3183
Current cigarette smoker 35 (28.0%) 28 (25.2%) 0.7391
Medications (pre-procedure)
ASA 113 (90.4%) 103 (92.8%) 0.6716
Clopidogrel 46 (36.8%) 45 (40.5%) 0.6491
Warfarin 10 (8.0%) 3 (2.7%) 0.1349
ASA  acetylsalicylic acid; BMI  body mass index; CAD  coronary artery disease; UFH unfractionated heparin.
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873arget vessel with no flow-limiting dissections or intravascular
hrombus formation as estimated by the operator after the
ntervention. Patients were monitored for in-hospital adverse
vents, such as unplanned percutaneous or surgical revascular-
zation for acute limb ischemia, subacute thrombosis, amputa-
ion before discharge, myocardial infarction, cerebrovascular
ccident, or death. These adverse events were considered
rocedure failures. The TIMI-1 trial (Thrombolysis In
yocardial Infarction Trial-Phase 1) definition of major
leeding was adopted and included intracranial or retroper-
toneal hemorrhage, a fall in hemoglobin of 5 g/dl, and/or
ransfusion of 2 U of packed red blood cells (PRBCs) for
ny reason (8). Secondary end points included minor bleed-
ng (bleeding that did not meet the aforementioned crite-
ia), time to sheath removal, time to ambulation, length of
ospital stay, and cost analysis.
tatistical analysis. To achieve 80% power, assuming alpha
.5 and 2-tail, the study would require an excess of 769
ubjects/group. This number is not feasible, given the
esources at our facility. Therefore, our study will be
nderpowered to detect group differences (35% power). The
bjective of this study is to demonstrate statistical nonsig-
ificance between groups. Continuous variables were pre-
ented by either mean  SD or median with the 25th (Q1)
nd 75th (Q3) percentiles and compared by the Mann-
hitney U test. Categorical variables were presented as
ounts and percentages and compared by chi-square test and
isher exact test. All p values are 2-tailed, and statistical
ignificance was considered as p  0.05. All analyses were
erformed with SAS version 9.1 (SAS Institute, Inc.,
aleigh, North Carolina).
esults
aseline demographic data and clinical characteristics of
oth groups are shown in Table 1. Various peripheral
ascular interventions were performed (Table 2). Sheath
izes, number of closure devices, and ACT values are shown
n Table 2.
Procedural success was achieved in 98% (n  122) of the
25 patients receiving bivalirudin versus 99% (n  110) of
he 111 patients with low-dose UFH (p  NS). Of the 3
atients in the bivalirudin group with unsuccessful proce-
ures, 1 had in-stent restenosis and 2 had post-procedural
esidual stenosis of 20%. The patient with in-stent reste-
osis underwent successful repeat angioplasty, and 1 of the
atients with post-procedural residual stenosis of 20%
nderwent amputation for osteomyelitis. One patient in the
FH group showed only minimal improvement of blood
ow after percutaneous manual thrombectomy; therefore,
urgical thrombectomy was recommended. Duration of
rocedure was 61.4  31.3 min for bivalirudin and 50 
0.9 min for UFH. Major bleeding occurred in 2.4% (n 
) of the patients with bivalirudin versus 0.9% (n  1) with fFH (p  NS). Two patients in the bivalirudin group
equired a transfusion of 2 U of PRBCs with no obvious
ource of bleeding, and 1 suffered a gastrointestinal bleed
equiring a transfusion of 3 U of blood. This patient had
aseline hemoglobin of 10 and hematocrit of 30.3, which
ere reduced after the procedure to 8.4 and 25.2, respec-
ively. Heme-positive stools were noted, and the patient
lected outpatient gastroenterologic work-up, which he
ailed to complete. He returned to the hospital 2 weeks later
ith hemoglobin of 6.6. Endoscopy revealed intestinal
rteriovenous malformations, and the patient was treated
er gastroenterology’s recommendations. One patient in the
FH group sustained a major bleed secondary to retroper-
toneal hemorrhage and required 5 U of PRBCs. This
atient unfortunately did not have documented ACT levels, an
rterial closure device was not used, and therefore the exact
eason for the hemorrhage can only be postulated to be a high
rterial access; antegrade approach was used for PPI; however,
n fluoroscopy the femoral head was not recorded on cine to
stimate the location of the arterial access. Table 3 shows the
rimary end points.
Minor bleeding occurred in 11 patients in each group.
ne bivalirudin patient sustained a pseudoaneurysm, which
as treated successfully with a thrombin injection. Ten
ivalirudin and 11 heparin patients were observed to have
uncture-site oozing and/or a small hematoma (4 cm
iameter), requiring prolonged bed rest and/or 2 to 4 h of
Table 2. Target Artery Sheath Sizes, Closure Devices, and ACT Values
Bivalirudin
(n  125)
UFH
(n  111) p Value
Artery
Subclavian 1 (0.8%) 4 (3.6%) 0.2993
Renal 17 (13.6%) 16 (14.4%) 0.9928
Iliacs 41 (32.8%) 34 (30.6%) 0.8282
Femoral 9 (7.2%) 8 (7.2%) 0.8034
Profunda 2 (1.6%) 2 (1.8%) 0.6995
SFA 65 (52.0%) 45 (40.5%) 0.1029
Popliteal 19 (15.2%) 9 (8.1%) 0.1389
Below the knee 14 (11.2%) 18 (16.2%) 0.3503
Celiac 0 (0.8%) 1 (0.9%) 0.5300
SMA 2 (1.6%) 1 (0.9%) 0.9180
Sheath sizes used
5-F 8 (6.4%) 8 (7.2%) 0.9904
6-F 65 (52.0%) 73 (65.8%) 0.0444
7-F 43 (34.4%) 24 (21.6%) 0.0425
8-F 9 (7.2%) 6 (5.4%) 0.7680
Closure devices used 11 (8.8%) 5 (4.5%) 0.2928
ACT values
5 min 328 68.7 236 61.4 0.001
30 min 325 67.6 223 56.4 0.001
ACTactivatedclotting time; SFA superficial femoral artery; SMA superiormesenteric artery;
UFH unfractionated heparin.emoral-stop placement (p  NS). Secondary outcomes
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874i.e., minor bleeding, time to ambulation, and the average
ospital course duration) were also similar (p  NS)
Table 3). Time to ambulation was 6.14  1.83 h vs. 6.12
1.37 h and duration of hospital stay was 45.33 vs.
4.26 average hours in the bivalirudin and UFH groups,
espectively. Time to sheath removal was 2.15  0.77 h
s. 2.49  1.33 h (p  0.0065) in the bivalirudin and
FH groups, respectively.
The hospital costs for bivalirudin and UFH are dramat-
cally different. The cost for bivalirudin in our facilities is
547 for a 250-mg vial. Renal dosing adjustments made no
ifference in cost, because the minimum charge for biva-
irudin was for 1 vial; and no patient in the study required
ore than 1 vial. Weight-based dosing of UFH varied per
atient, with a basic hospital cost of $0.61/1-ml vial of
,000 U; and no patient in the study required more than 2
ials of UFH. The hospital cost for an ACT level is $2.00.
iscussion
nfractionated heparin historically has been the primary
nticoagulant used in percutaneous interventions, and in
any instances, it is now being replaced with bivalirudin.
here are no randomized trials directly comparing bivaliru-
in to UFH in PPI. The results of multiple coronary studies
emonstrating the procedural success and bleeding/ischemic
omplications have been extrapolated into anticoagulation
trategies used currently in PPI. No American College of
ardiology/American Heart Association guidelines exist
pecifying the anticoagulation strategy in peripheral inter-
ention (1).
Procedural success with either anticoagulant has been
stablished as similar in multiple coronary and peripheral
tudies (5–7,9–12). Regarding long-term success, Allie
t al. (12) showed that, in addition to similar rates of initial
rocedural success, the 6-month ultrasound follow-up rates
f50% restenosis in 4% to 5% of patients were also similar
etween both anticoagulant groups in renal and iliac inter-
ention. Our study also showed procedural success rates of
8% vs. 99% in bivalirudin and UFH, respectively. Thus, it
Table 3. Primary and Secondary End Points
Bivalirudin
Primary end points
Procedure success 122 (
Secondary end points
Major bleeding 4 (
Minor bleeding 11 (
Time to sheath removal (h) 2.15
Time to ambulation (h) 6.19
Median duration of hospital stay (h) 24.0 (Q1–Q
UFH unfractionated heparin.eems that neither anticoagulant provides additional benefit oith achieving immediate or long-term procedural success.
owever, whether either anticoagulant will provide benefit
n maintaining a luminal diameter will require studies with
ong-term follow-up.
Major and minor bleeding complication rates after PCI
ave been reported to be as high as 13% and 26% with
FH, versus 4% and 9% with bivalirudin, respectively
5–7,10–13). There are a number of factors that might have
ontributed to these results, such as higher dosing of UFH
nd the use of UFH in combination with GP IIb/IIIa
nhibitors. When high doses of bivalirudin (1-mg/kg bolus,
-h infusion at 2.5 mg/kg/h and then up to 20-h infusion at
.2 mg/kg/h) and UFH (175-U/kg bolus followed by 15
/kg/h for up to 24 h) were used, major bleeding was found
o be 3.5% vs. 9.3%, respectively (6). In the REPLACE-2
Randomized Evaluation of PCI Linking Angiomax to
educed Clinical Events) trial (5), lower doses of bivaliru-
in (0.75-mg/kg bolus/1.75 mg/kg/h) and UFH (65-U/kg
olus, ACT 225 s) administered with a GP IIb/IIIa
nhibitor resulted in reduced rates of major bleeding at 2.4%
s. 4.1%, respectively. The ACUITY (Acute Catheteriza-
ion and Urgent Intervention Triage Strategy) trial (7)
eported no statistically significant differences in major or
inor bleeding rates when the use of bivalirudin alone was
ompared with the use of UFH; however, when UFH was
sed in combination with a GP IIb/IIIa inhibitor, signifi-
ant differences in major (3% vs. 5.7%, p  0.001) and
inor (3.7% vs. 6.4%, p  0.001) bleeding were found. A
mall, retrospective PPI study showed no statistical differ-
nces in rates of major and minor bleeding when bivalirudin
as compared with low-dose UFH (10). Therefore, the
igher bleeding complications seen in the coronary studies
entioned might be secondary to the higher doses of UFH
sed and/or the use of GP IIb/IIIa inhibitors. Similarly, our
tudy showed no statistical difference in major and minor
leeding rates when bivalirudin alone was compared with
ow-dose UFH in PPI.
Activated clotting time is used to follow the level of
nticoagulation during interventions, but the optimal ACT
125) UFH (n  111) p Value
110 (99.1%) 0.6245
1 (0.9%) 0.3741
10 (9.0%) 0.9551
2.49 1.13 0.0065
6.1 1.37 0.7384
–36.0) 24.0 (Q1–Q3: 20.0–40.0) 0.3819(n 
97.6%)
3.2%)
8.8%)
 0.77
 1.75
3: 18.5r UFH dosing during peripheral vascular interventions has
n
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875ot been defined. In a meta-analysis (14), an ACT of
pproximately 375 s was defined as optimal to prevent
schemic complications when UFH was used for PCI.
owever, this degree of anticoagulation is associated with
ncreased risk of bleeding, specifically in patients undergo-
ng complex peripheral arterial procedures. In 2006,
apuano et al. (15) demonstrated the safety and efficacy of
n ACT 200 s in conjunction with the use of standard
ntiplatelet therapy in patients undergoing PCI. In-hospital
omplication rates after percutaneous angioplasty have been
eported at a range of 3.5% to 32.7% in PPI (11). Shammas
t al. (9) reported an overall complication rate of 9.2% in
atients who received anticoagulation with heparin during
PI. In their study, they acknowledged that ACTs were not
vailable in all patients; however, their measured ACTs
ere relatively high, with 42.1% of patients having an ACT
400 s (9). There was no correlation in our study among
CT levels, sheath size, or time to sheath removal and
leeding risk. No published data attribute a causative
elationship between these factors and higher rates of
leeding complications. Prior publications do link higher
osages of UFH with a trend toward higher rates of
omplications (9). In our study, ACTs averaged approxi-
ately 330 and 230 s in the bivalirudin and UFH groups,
espectively, with much lower rates of major and minor
leeding. There was no correlation between ACT levels and
ajor/minor bleeding.
Time to sheath removal, measured from the time of
rocedure completion, was 2.15  0.77 h vs. 2.49  1.33 h
p  0.0065) in the bivalirudin and UFH groups, respec-
ively. This difference can theoretically be accounted for by
he fact that UFH half-life is 3 times that of bivalirudin and
s possibly due to nursing delays in obtaining the required
CT 160 s before sheath removal. Per protocol, the
ivalirudin patients had their sheaths removed 2 h after
rocedure completion. The fact that time to ambulation and
verall duration of hospital course was not statistically
ignificant suggests that time to sheath removal is clinically
elevant only with regard to patient comfort, secondary to
uration of required bed rest.
In our study, the cost of bivalirudin at $547 is hard to
ustify, because similar procedural success and in-hospital
omplication rates are seen when using UFH at a cost less
han approximately $6.00 (2 vials of UFH [10,000 U] and
ACT level checks). The limitations of UFH use are
ell-recognized. They include activation of platelets, unpre-
ictable dosing, and the potential for heparin-induced
hrombocytopenia (16). Multiple coronary studies have
hown decreased ischemic and bleeding complication with
ivalirudin (5–7). However, as mentioned earlier, these
esults might have been secondary to higher doses of UFH
sed and/or because UFH was used in combination with a
P IIb/IIIa inhibitor. If further studies reveal there is noustained long-term ischemic benefit associated with the usef bivalirudin in peripheral intervention in addition to no
n-hospital benefit, then the cost of bivalirudin can only be
ustified if the use of a GP IIb/IIIa inhibitor is required or
here is a contraindication to heparin, such as allergy or a
istory of heparin-induced thrombocytopenia. An addi-
ional advantage to choosing UFH during PPI is that
rotamine sulfate is readily available to reverse the antico-
gulation, if necessary.
tudy limitations. The study was small, nonblind, and
onrandomized. To prove noninferiority between both
roups regarding procedural success and bleeding compli-
ations, it would be necessary to study a cohort of at least
70 patients in each group so that the study would be
ufficiently powered. Unfortunately, due to the limitations
f resources at our facility, we were not able to conduct a
tudy of this magnitude. And the question remains: Does
ither anticoagulant provide long-term benefit?
onclusions
ow-dose UFH is equally as effective and safe as bivalirudin
hen used as an anticoagulation strategy in patients under-
oing PPI. In addition, use of low-dose UFH is less costly
han bivalirudin. Larger randomized studies are required to
urther evaluate these findings.
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